Sterna biologicals GmbH & Co. KG today announced that the Company will participate in the upcoming BIO-Europe® 2018 – 24th Annual International Partnering Conference taking place from November 5 to 7, 2018 in Copenhagen, Denmark.
Marburg, Germany, October 17, 2018 – Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today announced that the Company will participate in the upcoming BIO-Europe® 2018 – 24th Annual International Partnering Conference taking place from November 5 to 7, 2018 in Copenhagen, Denmark.
“Shortly after successfully completing our device feasibility studies with our asthma drug candidate SB010 and presenting encouraging phase IIa data with our GATA-3 specific DNAzyme SB012 in patients with moderate to severe ulcerative colitis, we believe this is an ideal time to discuss these results and our future development strategy with a wide range of industry experts,” said Christian Pangratz, CEO and Managing Director of sterna. “I am convinced that sterna is well positioned for future growth. Within the past ten years, the Company has grown into an accomplished immunology player with a total of four promising Phase II programs.”
Christian Pangratz, sterna’s CEO and Managing Director, will be available for one-on-one meetings with interested parties over the course of the conference.
Parties interested in meeting with sterna biologicals at BIO-Europe® 2018 are requested to send an invitation through the event’s partneringONE® partnering software or to contact info@sterna-biologicals.com, the Company will also be available for media interviews and background discussions.
ABOUT BIO-EUROPE®
BIO-Europe is the preeminent partnering conference of the European life science industry, bringing together international decision makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities and private one-to-one meetings. The BIO-Europe 2018 partnering event is expected to draw over 4,000 industry attendees for three days of high-level networking, representing upwards of 2,000 companies from over 60 countries. To learn more about the conference, please visit https://ebdgroup.knect365.com/
ABOUT STERNA BIOLOGICALS
Sterna biologicals GmbH & Co. KG is an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and ulcerative colitis. By targeting transcription factors that play a central role in regulating Th1- and Th2-driven inflammatory mechanisms, the Company’s proprietary DNAzyme-based drug candidates can intervene with upstream inflammatory processes to address related diseases more effectively. Sterna has currently four programs in Phase 2 development.
For more information, please visit www.sterna-biologicals.com.
